Sotiris Stergiopoulos

Dr. Sotirios G. Stergiopoulos is a Physician Executive with leading expertise in the field of pharmaceutical biotechnology. He holds appointment of President and Chief Executive Officer of A2A Pharmaceuticals and maintains a seat on the Board of Directors. He has held the position as Founder and Chairman of the Board since 2016. Dr. Stergiopoulos is a co-founder and former Independent Director of the Board for Biomea Fusion (BMEA) as well Director on the Board of Ricovr Healthcare. Dr. Stergiopoulos is also a Mentor at the Center for Innovation and Entrepreneurship “Archimedes” at the National and Kapodistrian University of Athens and a Board Member of the Modern Sport Communication, Journalism, and Photo Press masters program of the University of Peloponnese. Dr. Stergiopoulos’ previous experience includes Chief Medical Officer and SVP and Head of Global Medical Affairs at Ipsen and leading roles in Oncology R&D in companies such as Bayer, Celgene and Novartis. He has held appointments as an Attending Physician and trained in institutions such as Albert Einstein College of Medicine, Harvard Medical School and the National Institutes of Health. He earned a master’s in biotechnology enterprise and entrepreneurship (MBEE) from The Johns Hopkins University and a Medical Degree from Poznan University of Medical Sciences (Poland). Dr. Stergiopoulos has been elected a Fellow of the American College of Physicians, Fellow of the New York Academy of Medicine as well as the Fellow Royal Society of Medicine (UK), Member of the Royal College of Physicians (MRCP) and Sigma Xi Research Honor Society. He is also a Member of the American Association for Cancer Research (AACR) and of the American Society of Clinical Oncology (ASCO).

Dr. Stergiopoulos has held the role of Chairman of Scholarships for the Hellenic Medical Society since 2016 as well as President and Chairman of Medical Scholarships for the Order of AHEPA, Delphi Chapter No. 25. Dr. Stergiopoulos has been awarded by the American Cancer Society (ACS) for his “Longstanding Dedication and Commitment to Fighting Cancer.”